JT
So it probably didn't quite fit as a license opportunity. I -- are there other structures that, that might work? I think you at this conference last year asked me about M&A. I've been asked about M&A every -- throughout the 11 years that I've been here. I can't control that, but that probably would have been -- that would be a solution to this royalty approach. Right now, we're focusing on that, which we can control, which is the execution side of things, where we know that those companies are certainly aware of what we're doing. And we think with added clarity -- I mean, even the -- I think even the launch of the generic by Hikma ironically provide some substance, right? Okay, now we know, yes, it's sort of limited supply and it's not high price. The more we can answer and just nail down and take away the uncertainty, I think that helps with investors. I think that helps with strategic options as well.
Yee
And one of those is just get -- let's get the approval of Europe. Once that's nailed down and a label, that would be final visibility on that. So, look, I think that was really helpful. I think that makes sense, the royalty part and the margins and how that makes it challenging for people, and you are open to scenarios and to create value for that, and you've been buying stock. So, John, thank you very much for the update. Be safe for the rest of the year. We look forward to this together with you across U.S. and Europe. And we always appreciate your time.
So it probably didn't quite fit as a license opportunity. I -- are there other structures that, that might work? I think you at this conference last year asked me about M&A. I've been asked about M&A every -- throughout the 11 years that I've been here. I can't control that, but that probably would have been -- that would be a solution to this royalty approach. Right now, we're focusing on that, which we can control, which is the execution side of things, where we know that those companies are certainly aware of what we're doing. And we think with added clarity -- I mean, even the -- I think even the launch of the generic by Hikma ironically provide some substance, right? Okay, now we know, yes, it's sort of limited supply and it's not high price. The more we can answer and just nail down and take away the uncertainty, I think that helps with investors. I think that helps with strategic options as well.
Yee
And one of those is just get -- let's get the approval of Europe. Once that's nailed down and a label, that would be final visibility on that. So, look, I think that was really helpful. I think that makes sense, the royalty part and the margins and how that makes it challenging for people, and you are open to scenarios and to create value for that, and you've been buying stock. So, John, thank you very much for the update. Be safe for the rest of the year. We look forward to this together with you across U.S. and Europe. And we always appreciate your time.